173 related articles for article (PubMed ID: 33724834)
1. Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention.
Whitfield H; Hemmings AM; Mills SJ; Baker K; White G; Rushworth S; Riley AM; Potter BVL; Brearley CA
J Med Chem; 2021 Apr; 64(7):3813-3826. PubMed ID: 33724834
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for interdomain communication in SHIP2 providing high phosphatase activity.
Le Coq J; Camacho-Artacho M; Velázquez JV; Santiveri CM; Gallego LH; Campos-Olivas R; Dölker N; Lietha D
Elife; 2017 Aug; 6():. PubMed ID: 28792888
[TBL] [Abstract][Full Text] [Related]
3. SHIP2: Structure, Function and Inhibition.
Thomas MP; Erneux C; Potter BV
Chembiochem; 2017 Feb; 18(3):233-247. PubMed ID: 27907247
[TBL] [Abstract][Full Text] [Related]
4. The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity.
Pesesse X; Moreau C; Drayer AL; Woscholski R; Parker P; Erneux C
FEBS Lett; 1998 Oct; 437(3):301-3. PubMed ID: 9824312
[TBL] [Abstract][Full Text] [Related]
5. Comparative mechanistic and substrate specificity study of inositol polyphosphate 5-phosphatase Schizosaccharomyces pombe Synaptojanin and SHIP2.
Chi Y; Zhou B; Wang WQ; Chung SK; Kwon YU; Ahn YH; Chang YT; Tsujishita Y; Hurley JH; Zhang ZY
J Biol Chem; 2004 Oct; 279(43):44987-95. PubMed ID: 15316017
[TBL] [Abstract][Full Text] [Related]
6. A new layer of phosphoinositide-mediated allosteric regulation uncovered for SHIP2.
Le Coq J; López Navajas P; Rodrigo Martin B; Alfonso C; Lietha D
FASEB J; 2021 Aug; 35(8):e21815. PubMed ID: 34314064
[TBL] [Abstract][Full Text] [Related]
7. Structural features of human inositol phosphate multikinase rationalize its inositol phosphate kinase and phosphoinositide 3-kinase activities.
Wang H; Shears SB
J Biol Chem; 2017 Nov; 292(44):18192-18202. PubMed ID: 28882892
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the substrate specificity of the inositol 5-phosphatase SHIP1.
Nelson N; Wundenberg T; Lin H; Rehbach C; Horn S; Windhorst S; Jücker M
Biochem Biophys Res Commun; 2020 Apr; 524(2):366-370. PubMed ID: 32005521
[TBL] [Abstract][Full Text] [Related]
9. Expression, Purification, Crystallisation and X-ray Crystallographic Analysis of a Truncated Form of Human Src Homology 2 Containing Inositol 5-Phosphatase 2.
Le Coq J; Heredia Gallego L; Lietha D
Protein J; 2016 Jun; 35(3):225-30. PubMed ID: 27170292
[TBL] [Abstract][Full Text] [Related]
10. Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease.
Lim JW; Kim SK; Choi SY; Kim DH; Gadhe CG; Lee HN; Kim HJ; Kim J; Cho SJ; Hwang H; Seong J; Jeong KS; Lee JY; Lim SM; Lee JW; Pae AN
Eur J Med Chem; 2018 Sep; 157():405-422. PubMed ID: 30103190
[TBL] [Abstract][Full Text] [Related]
11. The association between the SH2-containing inositol polyphosphate 5-Phosphatase 2 (SHIP2) and the adaptor protein APS has an impact on biochemical properties of both partners.
Onnockx S; De Schutter J; Blockmans M; Xie J; Jacobs C; Vanderwinden JM; Erneux C; Pirson I
J Cell Physiol; 2008 Jan; 214(1):260-72. PubMed ID: 17620296
[TBL] [Abstract][Full Text] [Related]
12. PTEN and Other PtdIns(3,4,5)P
Csolle MP; Ooms LM; Papa A; Mitchell CA
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33276499
[TBL] [Abstract][Full Text] [Related]
13. SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels.
Giuriato S; Pesesse X; Bodin S; Sasaki T; Viala C; Marion E; Penninger J; Schurmans S; Erneux C; Payrastre B
Biochem J; 2003 Nov; 376(Pt 1):199-207. PubMed ID: 12885297
[TBL] [Abstract][Full Text] [Related]
14. The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity.
Vandeput F; Backers K; Villeret V; Pesesse X; Erneux C
Cell Signal; 2006 Dec; 18(12):2193-9. PubMed ID: 16824732
[TBL] [Abstract][Full Text] [Related]
15. A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery.
Mills SJ; Persson C; Cozier G; Thomas MP; Trésaugues L; Erneux C; Riley AM; Nordlund P; Potter BV
ACS Chem Biol; 2012 May; 7(5):822-8. PubMed ID: 22330088
[TBL] [Abstract][Full Text] [Related]
16. SHIPping out diabetes-Metformin, an old friend among new SHIP2 inhibitors.
Lehtonen S
Acta Physiol (Oxf); 2020 Jan; 228(1):e13349. PubMed ID: 31342643
[TBL] [Abstract][Full Text] [Related]
17. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.
Bago R; Malik N; Munson MJ; Prescott AR; Davies P; Sommer E; Shpiro N; Ward R; Cross D; Ganley IG; Alessi DR
Biochem J; 2014 Nov; 463(3):413-27. PubMed ID: 25177796
[TBL] [Abstract][Full Text] [Related]
18. Regulation of PDGF-stimulated SHIP2 tyrosine phosphorylation and association with Shc in 3T3-L1 preadipocytes.
Artemenko Y; Gagnon A; Ibrahim S; Sorisky A
J Cell Physiol; 2007 Jun; 211(3):598-607. PubMed ID: 17219406
[TBL] [Abstract][Full Text] [Related]
19. Small molecule targeting of SHIP1 and SHIP2.
Kerr WG; Pedicone C; Dormann S; Pacherille A; Chisholm JD
Biochem Soc Trans; 2020 Feb; 48(1):291-300. PubMed ID: 32049315
[TBL] [Abstract][Full Text] [Related]
20. Evidence of SHIP2 Ser132 phosphorylation, its nuclear localization and stability.
Elong Edimo W; Derua R; Janssens V; Nakamura T; Vanderwinden JM; Waelkens E; Erneux C
Biochem J; 2011 Nov; 439(3):391-401. PubMed ID: 21770892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
